FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2218730670> ?p ?o ?g. }

• W2218730670 endingPage "1167" @default.
• W2218730670 startingPage "1158" @default.
• W2218730670 abstract "Both the number and size of tumours in NF1 patients increase in response to the rise in steroid hormones seen at puberty and during pregnancy. The size of tumours decreases after delivery, suggesting that hormone-targeting therapy might provide a viable new NF1 treatment approach. Our earlier studies demonstrated that human NF1 tumour cell lines either went through apoptosis or ceased growth in the presence of 2-methoxyoestradiol (2ME2), a naturally occurring anticancer metabolite of 17-β estradiol. Previous reports of treatment with sulfamoylated steroidal and non-steroidal derivatives of 2ME2 showed promising reductions in tumour burden in hormone-responsive cancers other than NF1. Here we present the first studies indicating that 2ME2 derivatives could also provide an avenue for treating NF1, for which few treatment options are available. STX3451, (2-(3-Bromo-4,5-dimethoxybenzyl)-7-methoxy-6-sulfamoyloxy-1,2,3,4-tetrahydroisoquinoline), a non-steroidal sulphamate analogue of 2ME2, was tested in dose-dependent studies of malignant and benign NF1 human tumour cell lines and cell lines with variable controlled neurofibromin expression. The mechanisms of action of STX3451 were also analysed. We found that STX3451-induced apoptosis in human malignant peripheral nerve sheath tumour (MPNST) cell lines, even in the presence of elevated oestrogen and progesterone. It inhibits both PI3 kinase and mTOR signalling pathways. It disrupts actin- and microtubule-based cytoskeletal structures in cell lines derived from human MPNSTs and in cells derived from benign plexiform neurofibromas. STX3451 selectively kills MPNST-derived cells, but also halts growth of other tumour-derived NF1 cell lines. STX3451 provides a new approach for inducing cell death and lowering tumour burden in NF1 and other hormone-responsive cancers with limited treatment options." @default.
• W2218730670 created "2016-06-24" @default.
• W2218730670 creator A5004708346 @default.
• W2218730670 creator A5006667888 @default.
• W2218730670 creator A5006991208 @default.
• W2218730670 creator A5011135921 @default.
• W2218730670 creator A5012630911 @default.
• W2218730670 creator A5019630008 @default.
• W2218730670 creator A5024814449 @default.
• W2218730670 creator A5038771326 @default.
• W2218730670 creator A5039491508 @default.
• W2218730670 creator A5055207921 @default.
• W2218730670 creator A5078928249 @default.
• W2218730670 creator A5090143109 @default.
• W2218730670 date "2015-10-01" @default.
• W2218730670 modified "2023-10-10" @default.
• W2218730670 title "Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol" @default.
• W2218730670 cites W1502777806 @default.
• W2218730670 cites W1965703662 @default.
• W2218730670 cites W1966108836 @default.
• W2218730670 cites W1970203467 @default.
• W2218730670 cites W1972802699 @default.
• W2218730670 cites W1974744898 @default.
• W2218730670 cites W1976009942 @default.
• W2218730670 cites W1976061939 @default.
• W2218730670 cites W1978222675 @default.
• W2218730670 cites W2002973513 @default.
• W2218730670 cites W2008377983 @default.
• W2218730670 cites W2025079965 @default.
• W2218730670 cites W2026322409 @default.
• W2218730670 cites W2041029556 @default.
• W2218730670 cites W2042230351 @default.
• W2218730670 cites W2049225812 @default.
• W2218730670 cites W2054902030 @default.
• W2218730670 cites W2055550486 @default.
• W2218730670 cites W2063324806 @default.
• W2218730670 cites W2066278568 @default.
• W2218730670 cites W2068231017 @default.
• W2218730670 cites W2069386703 @default.
• W2218730670 cites W2071893342 @default.
• W2218730670 cites W2073513712 @default.
• W2218730670 cites W2080262492 @default.
• W2218730670 cites W2081225293 @default.
• W2218730670 cites W2085993615 @default.
• W2218730670 cites W2086526874 @default.
• W2218730670 cites W2087065591 @default.
• W2218730670 cites W2094454542 @default.
• W2218730670 cites W2097812689 @default.
• W2218730670 cites W2099257982 @default.
• W2218730670 cites W2107078161 @default.
• W2218730670 cites W2115772647 @default.
• W2218730670 cites W2116895128 @default.
• W2218730670 cites W2124366340 @default.
• W2218730670 cites W2136196488 @default.
• W2218730670 cites W2138879453 @default.
• W2218730670 cites W2141743782 @default.
• W2218730670 cites W2148849095 @default.
• W2218730670 cites W2154465669 @default.
• W2218730670 cites W2159096148 @default.
• W2218730670 cites W2161066917 @default.
• W2218730670 cites W2166435019 @default.
• W2218730670 cites W2171814777 @default.
• W2218730670 cites W2312282875 @default.
• W2218730670 cites W2323317437 @default.
• W2218730670 doi "https://doi.org/10.1038/bjc.2015.345" @default.
• W2218730670 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4647869" @default.
• W2218730670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26461061" @default.
• W2218730670 hasPublicationYear "2015" @default.
• W2218730670 type Work @default.
• W2218730670 sameAs 2218730670 @default.
• W2218730670 citedByCount "10" @default.
• W2218730670 countsByYear W22187306702018 @default.
• W2218730670 countsByYear W22187306702019 @default.
• W2218730670 countsByYear W22187306702022 @default.
• W2218730670 countsByYear W22187306702023 @default.
• W2218730670 crossrefType "journal-article" @default.
• W2218730670 hasAuthorship W2218730670A5004708346 @default.
• W2218730670 hasAuthorship W2218730670A5006667888 @default.
• W2218730670 hasAuthorship W2218730670A5006991208 @default.
• W2218730670 hasAuthorship W2218730670A5011135921 @default.
• W2218730670 hasAuthorship W2218730670A5012630911 @default.
• W2218730670 hasAuthorship W2218730670A5019630008 @default.
• W2218730670 hasAuthorship W2218730670A5024814449 @default.
• W2218730670 hasAuthorship W2218730670A5038771326 @default.
• W2218730670 hasAuthorship W2218730670A5039491508 @default.
• W2218730670 hasAuthorship W2218730670A5055207921 @default.
• W2218730670 hasAuthorship W2218730670A5078928249 @default.
• W2218730670 hasAuthorship W2218730670A5090143109 @default.
• W2218730670 hasBestOaLocation W22187306701 @default.
• W2218730670 hasConcept C121608353 @default.
• W2218730670 hasConcept C126322002 @default.
• W2218730670 hasConcept C134018914 @default.
• W2218730670 hasConcept C190283241 @default.
• W2218730670 hasConcept C2776260442 @default.
• W2218730670 hasConcept C2777477808 @default.
• W2218730670 hasConcept C502942594 @default.
• W2218730670 hasConcept C54355233 @default.
• W2218730670 hasConcept C55493867 @default.

• next